Paralos Bioscience Inc.

Paralos Bioscience Inc.

by | Mar 4, 2026

Paralos is developing the first-in-class phage-drug conjugate drug delivery platform, with lead asset targeting drug-resistant infections. Market Opportunity: Drug-resistant Gram-negative infections drive sepsis and pneumonia, extending ICU stays and costs; many...
MET Biotechnology

MET Biotechnology

by | Nov 8, 2025

MET Biotechnology develops technology platforms that enable multifunctional and programmable extracellular vesicle (EV)-based therapeutics. Market Opportunity: EVs are natural nanoscale carriers with potential for low immunogenicity, tissue targeting and engineered...
Adaptix

Adaptix

by | Feb 1, 2014

Adaptix (formerly Radius Diagnostics Research, Inc.) is revolutionizing the way 3D images are obtained. Adaptix Ltd is transforming radiology by essentially 'digitizing' the imaging source with a multitude of individually addressable emitters with integrated power...